(Q28307673)

Treatment of Complex Regional Pain Syndrome (CRPS) using low dose naltrexone (LDN)

Europe PubMed Central

19 July 2021

0 references

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

The science of fibromyalgia

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4)

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Low-dose naltrexone therapy improves active Crohn's disease

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Twenty years of research on cytokine-induced sickness behavior

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Oxycodone combined with opioid receptor antagonists: efficacy and safety

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Inflammation in complex regional pain syndrome: a systematic review and meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Immune-neural connections: how the immune system's response to infectious agents influences behavior

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Pharmacological characterization of LPS and opioid interactions at the toll-like receptor 4.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

(+)-naloxone, an opioid-inactive toll-like receptor 4 signaling inhibitor, reverses multiple models of chronic neuropathic pain in rats

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Naloxone inhibits immune cell function by suppressing superoxide production through a direct interaction with gp91phox subunit of NADPH oxidase

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Inhibitors of microglial neurotoxicity: focus on natural products

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Effects of the N-methyl-D-aspartate receptor on temporal summation of second pain (wind-up) in irritable bowel syndrome

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Low-dose naltrexone for disease prevention and quality of life

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Norman Cousins Lecture. Glia as the "bad guys": implications for improving clinical pain control and the clinical utility of opioids

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

A novel inhibitory effect of naloxone on macrophage activation and atherosclerosis formation in mice.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Is there a role for cytokine based therapies in fibromyalgia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Immune-to-brain communication dynamically modulates pain: physiological and pathological consequences

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Cytokine-induced sickness behavior.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

A novel effect of an opioid receptor antagonist, naloxone, on the production of reactive oxygen species by microglia: a study by electron paramagnetic resonance spectroscopy.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Naltrexone, opiate addiction, and endorphins

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Receptor binding, antagonist, and withdrawal precipitating properties of opiate antagonists.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Paradoxical hyperalgesic effect of exceedingly low doses of systemic morphine in an animal model of persistent pain (Freund's adjuvant-induced arthritic rats).

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

"Paradoxical" analgesia induced by naloxone and naltrexone

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Naltrexone Pharmacology, Pharmacokinetics, and Metabolism: Current Status

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Opioid antagonist modulation of murine neuroblastoma: a profile of cell proliferation and opioid peptides and receptors

2 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2517-2

Physical therapy modalities in management of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2517-2

Microglial activation involved in morphine tolerance is not mediated by toll-like receptor 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2517-2

A new concept affecting restoration of inflammation-reactive astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2517-2

The biology of the opioid growth factor receptor (OGFr)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2517-2

Elevated serum high-sensitivity C-reactive protein levels in fibromyalgia syndrome patients correlate with body mass index, interleukin-6, interleukin-8, erythrocyte sedimentation rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2517-2

Gene-peptide relationships in the developing rat brain: the response of preproenkephalin mRNA and [Met5]-enkephalin to acute opioid antagonist (naltrexone) exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2517-2

Signaling pathway of morphine induced acute thermal hyperalgesia in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2517-2

Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2517-2

Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2517-2

Naltrexone and nalmefene: any meaningful difference?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2517-2

The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2517-2

Bernard Bihari, MD: low-dose naltrexone for normalizing immune system function

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962576

Studies of EN-1639A (Naltrexone): A New Narcotic Antagonist

27 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24526250

12 December 2020

inferred from PubMed ID database lookup

Effects of Long-Term Treatment with Naltrexone on Hepatic Enzyme Activity

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24526250

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S10067-014-2517-2

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/urdvquctafa5bjnmdecruh2o7y

30 July 2022

release_urdvquctafa5bjnmdecruh2o7y

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/urdvquctafa5bjnmdecruh2o7y

30 July 2022

https://api.fatcat.wiki/v0/release/urdvquctafa5bjnmdecruh2o7y

1 reference

30 July 2022

https://api.fatcat.wiki/v0/release/urdvquctafa5bjnmdecruh2o7y

PubMed publication ID

1 reference

30 July 2022